Navigation Links
New Rheumatoid Arthritis Treatment

A new study shows a novel new drug is beneficial for patients with rheumatoid arthritis. The drug targets T cells and is the first in a new class of drugs to be tested for rheumatoid arthritis. //

The drug is called cytotoxic T-lymphocyte-associated antigen 4-IgG1 or CTLA4Ig. Preliminary research shows CTLA4Ig may be effective for the treatment of rheumatoid arthritis. Researchers from Belgium conducted a study to see if this drug is helpful for patients with rheumatoid arthritis.

Rheumatoid arthritis is a disease that causes progressive joint damage and disability. For the study, researchers assigned patients to receive one of two doses of CTLA4Ig or placebo. All of the patients also received methotrexate therapy during the study. Researchers assessed the patients after six months using the criteria of the American College of Rheumatology (ACR). The ACR defines the response to the treatment according to its extent. A 20 percent clinical response rate is noted as ACR 20, 50 percent is ACR 50, and 70 percent is ACR 70. Researchers also looked at the patients’ quality of life.

Researchers report the patients treated with the higher dose of CTLA4Ig were more likely to have an ACR 20 than patients who received placebo. Higher rates of ACR 50 and ACR 70 were seen in both groups on the drug compared to placebo. The patients on the higher dose of the drug also saw improvements in eight measures of quality of life.

Study authors conclude the combination of CTLA4Ig and methotrexate improved the signs and symptoms of the disease, physical function, and quality of life in patients with rheumatoid arthritis. Researchers also say both doses of the drug were well tolerated by the patients. They say this study shows the value of this new class of drugs in the treatment of rheumatoid arthritis
'"/>




Page: 1

Related medicine news :

1. New treatment for Rheumatoid Arthritis
2. New Rheumatoid Arthritis Treatment
3. Consumption Of Red Meat Found To Double The Risk of Rheumatoid Arthritis
4. The Link Between Rheumatoid Arthritis And Heart Failure
5. Smoking during pregnancy increases risk of Rheumatoid Arthritis.
6. Good News For Those Of You Suffering From Rheumatoid Arthritis
7. Mineral Oil exposure increases risk of Rheumatoid Arthritis
8. Mineral Oil exposure increases risk of Rheumatoid Arthritis
9. Novel drug holds promise for treatment of Rheumatoid Arthritis
10. Study Offers Insights Into Treatment Of Rheumatoid Arthritis
11. Protein Linked To Accelerating Rheumatoid Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe ... from the David Geffen School of Medicine at UCLA. He trained in Internal Medicine ... his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... A ... procedures that most people are unfamiliar with. The article goes on to state that ... but also many of these less common operations such as calf and cheek reduction. ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Scientific Sessions in Dallas that it will receive two significant new grants to ... came as PHA marked its 25th anniversary by recognizing patients, medical professionals and ...
(Date:6/24/2016)... ... ... makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a Fair Minimum ... by 2020 and then adjusting it yearly to increase at the same rate as the ... wage floor does not erode again, and make future increases more predictable. , The company ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® & Innovative Solutions today ... cultivation and processing operations at its production facility, and opened its first two ... the manufacturer of a complete system of proactive air and surface purification solutions ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... 2016 Jazz Pharmaceuticals plc (Nasdaq: ... Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR"), ... Inc. ("Celator"; Nasdaq: CPXX ) expired effective ... As previously announced on May 31, 2016, ... agreement under which Jazz Pharmaceuticals has commenced a tender ...
(Date:6/24/2016)... June 24, 2016  Consumers have taken a ... have placed more emphasis on patient outcomes. ... programs in the pharmaceutical industry have evolved beyond ... pharmaceutical companies are focusing on becoming more patient-oriented ... products and services that improve health. ...
(Date:6/24/2016)... , June 24, 2016   Bay Area ... Network,s Dean Center for Tick Borne Illness ... and Rehabilitation, MIT Hacking Medicine, University of California, ... today announced the five finalists of Lyme ... disease.  More than 100 scientists, clinicians, researchers, entrepreneurs, ...
Breaking Medicine Technology: